Precision Health Reports 📑❤️
@PreciseHlthRpt
Personalized insights for cardiometabolic disease to prevent heart attack, stroke, and type 2 diabetes—one person at a time. Member of @StartupHealth🚀
"Does cholesterol predict risk for cardiovascular diseases?" -- @Lipoprotein Here's the deal: cardiovascular disease risk is complicated. It's more than cholesterol, ApoB, insulin resistance, glucose, or inflammation. That's why the Cardiometabolic Risk Assessment considers…
🚨 ApoB and Lp(a) 🚨
📊 Not all apoB particles are created equal! New @EuroHeartJ study shows CAD risk rises with apoB count, but particle type & size matter too 🧬 A more nuanced view of atherogenic lipoproteins could refine risk stratification. 🔗 doi.org/10.1093/eurhea… #CardioTwitter…
Lab results aren’t good enough for personalized healthcare decision making.
"If your risk assessment doesn’t include ApoB and Lp(a), you’re not seeing the full picture." BOOM! 💣 Our Cardiometabolic Risk Assessment not only includes ApoB and Lp(a), it also integrates other outcome-proven biomarkers, adjusts for the individual person's clinical history,…
☝️No estimate of the apoB lipoprotein-related risk of CVD is complete without measurement of both apoB and Lp(a) ApoB is the true core marker of atherogenic particle burden, and Lp(a) is an independent, non-negotiable player in cardiovascular risk. ✅ ApoB reflects the number…
Everyone needs to have their Lipoprotein(a) measured.
Cardiovascular disease is NOT an old person's disease. The process starts early in life and continues later into life if not managed. Then it's an old person's disease. Start prevention early.
We don't know who needs to hear this, but this is not an effective strategy to reduce your cardiometabolic disease risk.
The greatest reduction in cardiovascular risk occurs with a reduction of particle number. Measuring your ApoB or LDL-P is critical. The lower the particle number attained, and the longer low particle number is maintained, the greater the reduction in cardiovascular risk.
CAC scans have their place, but in a more complete picture of an individual's risk factor puzzle. It's not uncommon for us to see someone at @PreciseHlthRpt with a very low pooled cohort score and moderate ApoB, but with a ratehr high CAC score (>50 at less than 50 y/o) and…
This is the answer from @EvidenceOpen when we asked: Q: "Why is Lp(a) undertested in the US despite being a significant independent risk factor for ACVD events?" A: Lipoprotein(a) [Lp(a)] is undertested in the United States despite being a significant independent risk factor…
We asked @EvidenceOpen: "Why is Lp(a) undertested in the US despite being a significant independent risk factor for ACVD events?" Any guesses what the answer was? Feel free to answer below before reading the answer that we post tomorrow.
You want to know the scoop on the Ashley St. Clair & Elon situation? Ok, here goes: Cardiometabolic disease risk detection and management requires looking at more than labs and CGM results. You have to start with “what do the guidelines based on long clinical trials say?” You…
There is no "one thing" silver bullet when it comes to metabolic health and cardiovascular disease. Thanks for coming to our Ted Talk.
It’s Valentine’s Day. When is the last time you checked your heart?
Don't wait until your own 2-minute warning to find your heart attack and stroke risk. #SuperBowlLIX